Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant canakinumab versus placebo after complete resection of NSCLC
MOH_2018-05-17_002315Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Canakinumab with Placebo (2 arms). Primary endpoints: Disease-free survival and Overall survival. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2018-05-17_002315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-17_002315.